A Study of Transition to the Paliperidone Palmitate 3-Month Formulation In Participants With Schizophrenia Previously Stabilized on the Paliperidone Palmitate 1-Month Formulation

Inclusion Criteria:

• Meets Diagnostic and Statistical Manual of Mental Disorders 5th edition (DSM-5)criteria for a diagnosis of schizophrenia

• Able to read, understand, and sign the informed consent form (ICF) indicating that heor she understands the purpose of and procedures required for the study and arewilling to participate in the study

• Willing and able to fill out self-administered questionnaires

• Willing and able to adhere to the prohibitions and restrictions specified in theprotocol

• A woman of childbearing potential must have a negative urine pregnancy test atScreening and baseline

• A woman must agree not to donate eggs (ova, oocytes) for the purposes of assistedreproduction during the study and for 6 months after receiving the last dose of studydrug

Exclusion Criteria:

• His/her psychiatric diagnosis is due to direct pharmacological effects of a substance (example, a drug of abuse or medication) or a general medical condition (example,clinically notable hypothyroidism, organic brain disorder)

• Experienced intolerable side effects during treatment with paliperidone palmitate 1-month formulation (PP1M)

• Has a known hypersensitivity to paliperidone or risperidone

• Has received any other long-acting injectable antipsychotic medication other thanPP1M within the last 4 months before the first injection of the study drugpaliperidone palmitate 3-month formulation (PP3M)

• Has received clozapine during the last 3 months before the Screening visit

• Is considered to be at imminent risk of suicide, even after clinical intervention

• Has a serious unstable medical condition, including recent and present clinicallyrelevant laboratory abnormalities

• Has a history or current symptoms of tardive dyskinesia or neuroleptic malignantsyndrome

• Is a woman who is pregnant or breast-feeding, or planning to become pregnant whileenrolled in this study or within 6 months after the last dose of PP3M

• Has participated in an investigational drug trial in the 30 days prior to theScreening visit or is currently enrolled in an investigational study

• Has a current DSM-5 diagnosis of dissociative disorder, bipolar disorder, majordepressive disorder, schizoaffective disorder, autistic disorder, or intellectualdisabilities and/or meets the DSM-5 definition of severe substance use disorder (except for nicotine and caffeine) within 6 months prior to screening; however,participants with mild or moderate substance use disorder, with the exception ofintravenous drug use, will be eligible for enrollment